Dr. Colin Walsh publishes study on fetal Trisomy 13

Dr. Colin Walsh publishes study on fetal Trisomy 13

Dr. Colin Walsh has recently published the results of a study in the prestigious American Journal of Medical Genetics. This novel study examines pregnancy outcomes in fetuses diagnosed with Trisomy 13 and was undertaken while Dr. Walsh was practicing overseas.

Dr. Colin Walsh publishes study on fetal Trisomy 13

A link to the recently published paper can be found here:

Trisomy 13, or Patau syndrome, is the 3rd most common fetal chromosomal abnormality. Despite this, it is still very rare, affecting less than 1 in 5,000 babies. Unfortunately, Patau syndrome is far more severe than Down syndrome and is generally considered to be a lethal abnormality.

In their recent study, Dr. Walsh and colleagues found that, in fetuses with Trisomy 13 confirmed on CVS or amniocentesis, only half of the babies were live-born. Of these, 80% passed away within the 1st day of life and no baby survived beyond 6 weeks of age. 1-in-10 women carrying a baby with Trisomy 13 developed pre-eclampsia. In all cases, significant fetal abnormalities were seen on fetal morphology scan, mainly heart, barin, facial and growth problems.

The probability of your baby having Trisomy 13 is routinely included in the Nuchal Translucency scan and in Non-Invasive Prenatal Testing. At SHORE for WOMEN, we are experts in options for prenatal screening and diagnosis of fetal chromosomal problems.

Please telephone or email us if you wish to make an appointment with Dr. Colin Walsh to discuss your options for prenatal screening for Trisomy 13, Down syndrome and other chromosomal problems.

  • Mater Hospital
  • North Shore Private Hospital
  • The University Of Sydney
  • Royal College Of Obstetricians and Gynaecologists